Rosenberg, 1985, N Engl J Med, 313, 1485, 10.1056/NEJM198512053132327
Rosenberg, 1984, Cancer Treat Rep, 68, 233
Rosenberg, 1985, JNCI, 75, 595
Mazumder, 1984, J Exp Med, 159, 495, 10.1084/jem.159.2.495
Mulé, 1984, Science, 225, 1487, 10.1126/science.6332379
Rosenberg, 1985, J Exp Med, 161, 1169, 10.1084/jem.161.5.1169
Mulé, 1985, J Immunol, 135, 646, 10.4049/jimmunol.135.1.646
Lafreniere, 1985, Cancer Res, 45, 3735
Lafreniere, 1985, J Immunol, 135, 4273, 10.4049/jimmunol.135.6.4273
Mazumder, 1984, Cancer, 53, 896, 10.1002/1097-0142(19840215)53:4<896::AID-CNCR2820530414>3.0.CO;2-E
Rosenberg, 1984, J Biol Response Mod, 3, 501
Lotze, 1985, J Immunol, 134, 157, 10.4049/jimmunol.134.1.157
Lotze, 1985, J Immunol, 135, 2865, 10.4049/jimmunol.135.4.2865
Yron, 1980, J Immunol, 125, 238, 10.4049/jimmunol.125.1.238
Lotze, 1980, J Immunol, 125, 1487, 10.4049/jimmunol.125.4.1487
Lotze, 1981, Cancer Res, 41, 4420
Grimm, 1982, J Exp Med, 155, 1823, 10.1084/jem.155.6.1823
Rosenstein, 1984, Cancer Res, 44, 1946
Rosenberg SA. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. In: De Vita VT, Hellman S, Rosenberg SA, eds. Important advances in oncology: Philadelphia: JB Lippincott, 1986:55–91.
Lotze, 1986, JAMA, 256, 3117, 10.1001/jama.1986.03380220083027
Muul, 1986, J Immunol Methods, 88, 265, 10.1016/0022-1759(86)90015-3
Rosenberg, 1984, Science, 223, 1412, 10.1126/science.6367046
Siegel, 1985, J Biol Response Mod, 4, 596
Atkins, 1986, J Clin Oncol, 4, 1380, 10.1200/JCO.1986.4.9.1380
Rosenstein, 1986, J Immunol, 137, 1735, 10.4049/jimmunol.137.5.1735
Rosenberg, 1986, Science, 233, 1318, 10.1126/science.3489291
